



Michael Chary, MD, PhD

Please share your current and past involvement in AACT, AACT-related activities and/or ABAT.

I have been the co-Chair of the Herbal and Dietary Supplements Section for the last four years. I attend NACCT and EAPCCT each year and have participated in the 2025 AACT ToxCoach as a mentor.

Please note any previous leadership and/or board experience(s) in other associations and/or institutions.

Within the American College of Medical Toxicology (ACMT), I have been an active contributor at the national level, serving on both the Research Committee and Practice Committee since 2021, supporting initiatives related to evidence generation, clinical guidance, and organizational priorities. I also founded and lead the AI Special Interest Group (2026–present), bringing together clinicians and researchers to advance the responsible integration of artificial intelligence into toxicology practice and research.

In 2025 I founded, Ariadne, that aims to increase long-term adherence to buprenorphine by reducing the burden of symptoms that lead to non adherence. Since 2025, I have also been the co-Director of webPOISONCONTROL.

Please share your vision and goals as a member of the Board of Trustees.

AACT is uniquely positioned to guide toxicology at a pivotal moment. Technological advances allow toxicological guidance to move out of the call center to digital triage and data-driven discovery, but only if we responsibly use AI. My vision is to help AACT lead this evolution while preserving the rigor and clinical judgment that define our field.

I aim to strengthen three areas. First, access and reach: expanding how toxicology expertise is delivered, including through digital tools to meet patients where they are. Second, evidence generation from real-world data: leveraging sources such as poison center data, online platforms, and clinical registries to identify emerging exposures and potential therapeutics more rapidly. The strength is in using NPDS and generic codes as a unifying and harmonizing standard. Third, education and workforce development:

equipping current and future toxicologists with the skills to critically evaluate and responsibly use computational tools, including AI, without losing the fundamentals of clinical reasoning.

AACT can serve as the bridge between tradition and innovation, ensuring new technologies are clinically meaningful, interpretable, and aligned with patient care. As a Trustee, I will focus on pragmatic, high-impact initiatives that expand our field's visibility, strengthen its evidence base, and improve patient outcomes.

Professional Bio (150–200 words; will be used for the program/website)

Michael Chary, MD, PhD, is an Assistant Professor of Emergency Medicine at Weill Cornell Medicine and a practicing emergency physician and medical toxicologist. He serves as Co-Director of webPOISONCONTROL, an online toxicology triage tool, and founder of Ariadne, a digital platform to increase long-term adherence to buprenorphine.

Dr. Chary's work was among the first to demonstrate that online commentary can provide valid exposure information, including early warning signals and dose-effect associations. He has contributed to toxicology chapters in Rosen's Emergency Medicine and The Merck Manual, published more than 40 peer-reviewed papers, and his work has been presented at national and international toxicology meetings. His current projects explore how digital tools can augment poison control services and improve patient decision-making outside traditional healthcare settings.

His startup, Ariadne, was selected by the NIH as a winner of the "\$100,000 Start an SUD Startup" where promising companies receive bridge funding and mentorship for preparing an SBIR grant.

Dr. Chary is committed to advancing medical toxicology through innovation, education, and collaboration across clinical, public health, and technological domains.